Viruses as potential targets for therapy in HIV-associated malignancies

Hematology/Oncology Clinics of North America

Volumn 17, Issue 3, 2003, Pages 697-702

  Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; VACCINE;

ADOPTIVE IMMUNOTHERAPY; AIDS RELATED COMPLEX; ANTIGEN SPECIFICITY; CELL KILLING; DRUG TARGETING; EPSTEIN BARR VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0037711547     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00045-5     Document Type: Review

References (28)

1. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, et al, editors. Fields virology. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2511-93.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al, editors. Fields virology. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2575-627.
3. Moore PS, Chang Y. Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci 2001;356:499-516.
4. Ambinder RF, Lemas MV, Moore S, et al. Epstein-Barr virus and lymphoma. Cancer Treat Res 1999;99:27-45.
5. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995;332:1186.
6. Horenstein MG, Nador RG, Chadbum A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood 1997;90:1186-91.
7. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001;1:75-82.
8. Sitki-Green D, Edwards RH, Webster-Cyriaque J, et al. Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay. J Virol 2002;76:9645-56.
9. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:1-8.
10. Nagy S, Gyulai R, Kemeny L, et al. Iatrogenic Kaposi's sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230-1.
11. Savoldo B, Goss J, Liu Z, et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001; 72:1078-86.
12. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-42.
13. Orentas RJ, Lemas MV, Mullin MJ, et al. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J Hematother Stem Cell Res 1998;7:257-61.
14. Brander C, O'Connor P, Suscovich T, et al. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis 2001;184:119-26.
15. Brander C, Suscovich T, Lee Y, et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J Immunol 2000;165:2077-83.
16. Dantuma NP, Masucci MG. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies. Semin Cancer Biol 2003;13:69-76.
17. Lucas KG, Sun Q, Burton RL, et al. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther 2000;11:1453-63.
18. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55.
19. Rooney CM, Bollard C, Huls MH, et al. Immunotherapy for Hodgkin's disease. Ann Hematol 2002;81(Suppl 2):S39-42.
20. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-8.
21. Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001;93:706-13.
22. Gottschalk S, Edwards OL, Huls MH, et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003;101:1905-12.
23. Orentas RJ, Roskopf SJ, Nolan GP, et al. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol 2001;98:220-8.
24. Lin CL, Lo WF, Lee TH, et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002;62:6952-8.
25. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000;14:11-21.
26. Cannon JS, Hamzeh F, Moore S, et al. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999;73:4786-93.
27. Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082-91.
28. Takada K. Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol 2001;258:141-51.